
FDA Releases Draft Guidance on Population Pharmacokinetic Analysis
The new guidance offers information for new drug application and biologics license application sponsors regarding population pharmacokinetic analysis.
FDA published
The guidance lists common applications of population PK analysis to provide sponsors with illustrative examples. FDA provides data and model requirements, recommendations on drug labeling based on population PK analysis, and the format and content of population PK reports. Specifically, the guidance discusses selecting dosing regimens, sample sizing and scheme requirements, exposure metrics, pediatric study designs, and drug-drug interactions. Data topics discussed include study subjects, sampling schedules, preliminary examination of data, model development and validation, and simulations based on population PK models.
Comments on the guidance are being accepted through September 11, 2019.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.